Oligonucleotide Drugs for Transthyretin Amyloidosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed.

1. Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags.Scientific reports · 2025
   Article
2. A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Frontiers in medicine · 2024
   Review
3. 3-O-Methyltolcapone and Its Lipophilic Analogues Are Potent Inhibitors of Transthyretin Amyloidogenesis with High Permeability and Low Toxicity.International journal of molecular sciences · 2023
   Article
4. [Neurological manifestations of ATTR amyloidosis].Innere Medizin (Heidelberg, Germany) · 2023
   Review
5. Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment.EXCLI journal · 2023
   Review
6. Clinical trials in Charcot-Marie-Tooth disorders: a retrospective and preclinical assessment.Frontiers in neurology · 2023
   Article
7. Liver-directed drugs for transthyretin-mediated amyloidosis.Journal of the peripheral nervous system : JPNS · 2022
   Review
8. [Genetic distribution in Chinese patients with hereditary peripheral neuropathy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
   Article
9. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.International journal of molecular sciences · 2022
   Review
10. The Frequency of V122I Transthyretin Mutation in a Cohort of African American Individuals With Bilateral Carpal Tunnel Syndrome.Frontiers in neurology · 2022
    Article
11. Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability.Neurology · 2021
    Article
12. Recent Advances and Current Dilemmas in the Diagnosis and Management of Transthyretin Cardiac Amyloidosis.Journal of the American Heart Association · 2021
    Review
13. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
14. Cardiac Amyloidosis: A Review of Current Imaging Techniques.Frontiers in cardiovascular medicine · 2021
    Review
15. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.Stem cell reports · 2020
    Article
16. Evidence of Concurrent Light Chain and Transthyretin Cardiac Amyloidosis in 2 Patients.JACC. CardioOncology · 2020
    Review
17. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.Cells · 2020
    Review
18. Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA.Frontiers in pharmacology · 2020
    Review
19. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.Nature communications · 2019
    Article
20. Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant.Neurology. Genetics · 2019
    Article

Corrections and comments

• Comment on
  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.2018
• Comment on
  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as